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Abstract
Adenoviruses are one of the most genetically diverse DNA viruses and cause non-life-
threatening infections in the ocular, respiratory, or gastrointestinal epithelium of a diverse 
range of hosts. Adenoviruses are excellent vectors for delivering genes or vaccine antigens 
to the target host tissues and are being tested in several vaccine and gene therapy studies. 
Adenovirus-based vectors offer several advantages over other viral vectors such as broad 
range of tissue tropism, well-characterized genome, ease of genetic manipulation includ-
ing acceptance of large transgene DNA insertions, inherent adjuvant properties, ability 
to induce robust transgene-specific T cell and antibody responses, non-replicative nature 
in host, and ease of production at large scale. However, several studies have highlighted 
major drawbacks to using adenovirus as vaccine and gene therapy vectors. These include 
pre-existing immunity in humans, inflammatory responses, sequestering of the vector 
to liver and spleen, and immunodominance of the vector genes over transgenes. In the 
same vein, recently discovered protein sequence homology and heterologous immunity 
between adenoviruses and hepatitis C virus have significant implications in the use of 
adenoviral vectors for vaccine development, especially for hepatitis C virus. This chapter 
focuses on the current scope and challenges in using adenoviral vector-based vaccines 
and gene therapies.
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1. Introduction
Adenoviruses (Ads) are non-enveloped, icosahedral DNA viruses with virion size ranges 
between 70 and 90 nm [1]. They belong to a diverse family (>50 serotypes) of DNA viruses 
called adenoviridae. Adenovirus was first isolated from human adenoid tissues in 1953 by 
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Rowe and his colleagues [2]. Adenoviruses usually cause non-symptomatic respiratory tract 
infections in both human and animals but can be life-threatening to immunocompromised 
individuals. Certain human adenovirus serotypes are ubiquitous in children, and most adults 
carry neutralizing antibodies to adenoviruses [3]. Nonetheless, since their initial use in gene 
therapy, they have gained wide recognition as a vaccine antigen delivery vehicle and have 
proven to be safe and efficient vaccine vectors for eliciting protective immune responses 
against transgene antigens in many animal and human studies. Recently, adenovirus vectors 
have been employed to attack cancer cells in cancer therapy [4]. In this chapter, we introduce 
different adenoviruses and their biology and potential for use in gene delivery, vaccine, and 
therapeutics in several human diseases. In addition, we will discuss their limitations and 
future prospects.
2. Adenoviruses
2.1. Genome and proteins
Adenoviruses contain a 26–45 kb size double-stranded DNA genome, inside their icosahe-
dral virion [1]. The DNA genome of adenoviruses contains two inverted terminal repeats 
with 100–140 bp flanks on both the ends. Due to its small genome size, adenoviruses employ 
several strategies to maximally utilize its genome. For example, they encode proteins from 
both DNA strands, employ alternate-splicing, and use different poly A modifications of its 
mRNA. Adenoviral genes can be divided into five early and five late genes. Once internalized 
into target cells, the adenoviruses express the early genes E1A, E1B, E2, E3, and E4, which 
modulate host gene expression required for adenovirus protein synthesis and replication. The 
late transcriptional units include L1–L5 and are required in the assembly, release, and lysis of 
host cells [1, 5, 6] (Figure 1).
Structurally, adenovirus consists of a core of capsid and genome. The viral capsid con-
sists of structural proteins hexon, penton, fiber, IIIa, VIII, and IX. Hexons are major sur-
face structural proteins consisting of 270 trimers, which are arranged as 12 pentamers of 
pentons at the top of 12 icosahedral vertices. Hexons also contain several hypervariable 
regions and are the main targets of neutralizing antibodies. In adenoviral vectors, these 
sites can be engineered to carry vaccine antigen. Each icosahedral vertex gives rise to pro-
truding fibers consisting of 12 trimers. Both penton and fiber proteins serve as ligands for 
host cell receptors and help in viral entry. The IIIa proteins are located in the inner surface 
of the capsid and help in the assembly and stabilization of vertex regions and also in the 
assembly of packaged viral genome. The VI proteins link the outer capsid shell to the inner 
icosahedral shell. The VIII proteins help in bonding hexons together and are critical for 
the stability of the viral capsid. The proteins V, VII, and X are associated with the DNA 
genome and make up the virion core. Terminal protein binds to each end of the DNA 
genome [6–8] (Figure 1).
The early gene first transcribes E1A protein, an essential protein for viral replication. The E1A 
protein activates the transcription of other viral genes responsible for viral DNA synthesis. In 
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host cells, E1A stimulates apoptosis by both p53-dependent and -independent pathways [9]. In 
contrast, the E1B protein inhibits apoptosis by binding to several host cell proteins such as p53, 
Bak, and BAX proteins [8]. In non-replicating adenoviral vectors, the E1 gene is deleted to ren-
der them replication-defective so that it can infect the host cells but cannot multiply. However, 
for production of non-replicating adenoviral vectors, E1 transfected cells such as HEK293 and 
PER.C6 are used to allow production of replication-defective adenoviral vector [9].
2.2. Types of adenoviruses
Adenoviruses are grouped under the family Adenoviridae, which is divided into five genera: 
Mastadenovirus, Aviadenovirus, Siadenovirus, Atadenovirus, and Ichtadenovirus. Human 
adenoviruses, along with many animal adenoviruses (monkeys, cattle, sheep, swine, dogs), 
belong to the genus Mastadenovirus. Human adenoviruses (HAd) are classified into seven 
subgroups: A–G and further in to 67 serotypes based on serological properties. The classifica-
tion of serotypes into subgroups is based on their similarities in genome organization and 
DNA sequences, host tropism, carcinogenic potential in rodents, and growth properties in 
cell cultures. Adenoviral serotyping is based on viral surface antigen neutralizing antibodies 
and by phylogenetic distance (>10%) in the viral genes that encode viral protease, the protein 
pVIII, the hexon protein, and the DNA polymerase [10–12].
The genus Aviadenovirus contains bird adenoviruses, while other genera Siadenovirus, 
Atadenovirus, and Ichtadenovirus contain other adenoviruses of mammals, birds, reptiles, 
and fishes [13–15]. The adenoviruses isolated from sheep, cattle, deer, possum, and some 
birds differ from the adenoviruses of the genus Mastadenovirus and are classified under 
Figure 1. Adenovirus structure and genome organization. (A) Graphical representation of adenovirus structure and 
various proteins. (B) Adenovirus genome organization showing various early (E) and late (L) transcripts and proteins 
encoded by each transcript. Regions indicated by red with (*) are deleted in various adenoviral vectors. E1 and E3 
regions were deleted in first generation and E1, E2, E3, and/or E4 were deleted in second-generation adenoviral vectors. 
Most recent adenoviral vectors called helper-dependent adenoviral vectors only contain ITRs and packaging signals. 
Figure is adapted from Ref. [209].
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the genus Atadenovirus [6, 16, 17]. The adenoviruses of the genus Mastadenovirus have 
high A + T (adenine and thymidine)-rich genomes and lack the early region 1 (E1) tran-
scriptional unit. Adenoviruses isolated from many invertebrates are classified under the 
new genus Siadenovirus. Human and animal adenovirus infections are very common, and 
the majority of the population of host species contain neutralizing antibodies against the 
most prevalent serotypes of adenoviruses. Both human and non-human adenoviruses have 
been studied extensively and are the basis of adenoviral vector-based vaccine and gene 
therapies [18, 19]. In humans, infection by non-human adenovirus serotypes is not com-
mon. However, due to broad tissue tropism and structural and genomic similarity with 
human adenoviruses, non-human adenoviruses can infect various human tissue types. 
These properties of adenoviruses encouraged researchers to use non-human adenoviruses 
as gene or vaccine antigen delivery vectors to mitigate the pre-existing neutralizing immu-
nity that commonly exists against human adenoviral vectors. Several non-human adenovi-
ruses such as bovine Ad serotype 3 (BAd3); canine Ad serotype 2 (CAd2); chimpanzee Ad 
serotypes 1, 2, 3, 5, 6, 7 and 68 (ChAd1, ChAd2, ChAd3, ChAd5, ChAd6, ChAd7, ChAd68); 
ovine Ad serotype 7 (OAd7); porcine Ad serotype 3 and 5 (PAd3, PAd5); and fowl Ad 
serotypes 1, 8, 9, and 10 (FAd1, FAd8, FAd9, FAd10) are currently being tested as vaccine 
or gene delivery vectors [18, 20–22]. Extensive research in the molecular biology of both 
human and non-human Ads has helped in better understanding of the adenoviruses and 
designing of adenoviral vectors.
2.3. Immunity to adenoviruses
Initially, a host detects the invading virus by sensing unique pathogen-associated molecular 
patterns (PAMPs) present on the pathogen through pattern recognition receptors (PRRs). 
Once activated, these PRRs transmit signal to express type I interferons (IFNs) and proinflam-
matory cytokines which inhibit viral replication and recruit various innate immune cells to 
the site of infection [23–27]. These initial events ensure the efficient activation and presenta-
tion of viral antigens by the antigen-presenting cells to T cells and result in the induction of 
adaptive immune responses. In the following sections, we will discuss innate and adaptive 
immune responses to Adenoviruses in detail.
2.3.1. Innate immunity
Adenoviruses are known to induce robust innate immune responses in their hosts. The 
adenovirus binds to its receptor(s) (such as Coxsackie adenovirus receptor or CAR, inte-
grin αvβ5 heparin sulfate proteoglycans, CD46, sialic acid, etc.) on host cells and gains 
entry into the cytoplasm [28–32]. However, phagocytic antigen-presenting cells such as 
macrophages and dendritic cells can also take up virus particles through scavenger recep-
tors [33]. Inside a host cell, the virus can be recognized by various intracellular molecular 
sensors such as Toll-like receptors (TLRs), RIG-I like receptors (RLRs), nucleotide-binding 
oligomerization domain (NOD)-like receptors (NLRs), cytosolic DNA sensors, and effector 
molecules [34–36].
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Cytokines such as IL-8 and TNF-α enhance the entry of human adenovirus type C by increas-
ing the availability of CAR and integrin receptors, which facilitate the adenovirus to enter 
through clathrin-mediated dynamin-dependent endocytosis [27, 33, 37, 38]. The type B human 
adenoviruses use CD46 or desmoglein-2 and enter host cells through macropinocytosis [39, 
40]; this also results in the suppression of IFN-γ-induced production of proinflammatory 
cytokine IL-12 [41].
One of the major drawbacks of the use of adenovirus in gene therapy is the induction of unde-
sired innate immune responses. In liver and spleen, the resident macrophages can sense and 
trap blood-borne adenovirus and induce inflammatory response mediators [42, 43]. Adenovirus 
also activates TLR2-dependent expression of chemokines such as MCP-1 and RANTES. In 
mice, TLR2 deficiency resulted in reduced NF-κB activation and humoral responses to HAd 
vector antigens and transgene-encoded antigens [42]. However, TLR2 deficiency did not result 
in complete inhibition of acute and adaptive responses to HAd, suggesting the involvement of 
an additional pathway [44]. The cellular β3 integrins were recently reported to interact with 
arginine-glycine-aspartic acid (RGD) motifs of viral homo-pentameric penton base protein 
during viral entry, which results in the processing of inactive IL1α into active cytokine in a 
MyD88-, TRIF-, and TRAF6-independent signaling pathway [43]. The IL1α plays a major role 
in adenovirus-induced inflammatory responses. The IL1R-deficient mice or wild-type mice 
treated with anti-IL-1 antibodies demonstrated reduced inflammatory responses as well as 
hepatotoxicity in adenovirus infection [45]. Further, the interaction between the adenoviral 
RGD motif and host β3 integrin mediates chemokine secretion, leukocyte infiltration, as well 
as corneal inflammation in human adenovirus serotype 37 infections [46].
TLR9 also plays a significant role in innate immunity against adenoviruses. Macrophages have 
been reported to sense adenovirus, helper-dependent adenoviral vector and recombinant E1- 
and E3-deleted adenovirus through TLR9 [47, 48]. The TLR9-deficient mice show reduced 
proinflammatory responses and IFN-α production upon adenoviral vector delivery. In a 
mouse model pf keratitis, adenovirus induced TLR9-dependent IL6 production and mono-
cyte infiltration of the cornea; however, chemokine secretion and keratitis development were 
TLR9-independent [49, 50]. Another study showed that recombinant adenovirus-induced 
type I IFN production in plasmacytoid dendritic cells (pDCs) is TLR9-MyD88-dependent but 
in myeloid DCs (mDCs) and macrophages, it is TLR9-independent [48].
The viral DNA also plays a critical role in the induction of innate immune responses as empty 
adenoviral particles are found to be poor inducers of innate responses [51]. The presence of 
double-stranded RNA with 5′-triphosphate groups in the cytoplasm of target cells is sensed 
by cytosolic PRR such as RIG-I, and viral DNA and RNA are recognized by intracellular PRRs 
such as TLR3, 7, and 8 present on the endosomal membrane [48, 52–55]. The double-stranded 
DNA is sensed by TLR9 in the intracellular environment and also by DNA-dependent activator 
of IRFs (DAI), DNA-dependent protein kinase (DNA-PK), IFN-γ-inducible protein 16 (IFI16), 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 41 (DDX41), and by cyclic guanosine mono-
phosphate-adenosine monophosphate synthase (cGAS) [34, 35, 56, 57]. Other cytosolic viral 
DNA sensors are NOD-like receptors (NLRs), which consist of a central nucleotide-binding 
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domain responsible for ATP-dependent self-oligomerization, a C-terminal leucine-rich repeat 
(LRR) domain that senses the presence of a ligand, and a variable N-terminal interaction 
domain that mediates protein-protein interactions. The NLR activation leads to the formation 
of inflammasomes with the help of microtubules [58]. The human adenovirus activates the 
formation of two types of inflammasomes in myeloid cells: absent in melanoma-2 (AIM2) 
and NLR-pyrin domain (PYD)-containing protein (NALP3). The activation of inflammasomes 
induces inflammatory responses via NF-κB signaling, converts pro-IL1β and pro-IL18 into 
IL1β and IL18, respectively, and can lead to DNA fragmentation, membrane pore formation, 
and eventually cell death by pyroptosis [59].
The early adenoviral proteins E1, E3, and E4 interfere with the innate immune signaling 
and help in evading host immune responses. The E1A protein allows hijacking of cell cycle, 
inducing apoptosis, evading immuning, inducing tumorigenesis, and expressing viral genes 
[60, 61]. The E1A has been reported to block type 1 IFN-inducible gene expression [62–64], 
type 2 IFN-γ-dependent HLA class II expression, and IFN-β expression in response to dou-
ble-stranded RNA due to inhibition of transcription complex formation [62]. Furthermore, 
E1A inhibits IFN-alpha-stimulated transcription factor 3 (ISGF3), IFN-stimulated genes 
(ISGs) [65, 66], and immunoproteasomes, resulting in reduced antigen presentation to 
T cells [67]. In addition, the early adenoviral proteins E1B-19K and E1B-55K antagonize 
p53-mediated apoptosis [68, 69], and E1B-55K interferes with the induction of IFN-inducible 
genes [70, 71]. The E1B-55K and E4 proteins induce proteasome-mediated degradation of 
defense factor death domain-associated protein (Daxx) resulting in the removal of viral tran-
scription blocking allowing viral gene expression [72, 73]. E1B-55K and E4 protein complex 
also result in inhibition of antiviral innate immune responses [74–77]. The E3 protein has 
several immune modulatory functions. It blocks the surface transport of MHC-class I mol-
ecule and also reduces NK cell receptors on host cells, masking infected cells from detection 
by immune cells [78]. Furthermore, the E3 protein also inhibits apoptosis of adenovirus-
infected cells by downregulation of death receptors [79].
The induction of innate immune responses is critical in adenoviral vector-based strategies. 
On the one hand, the gene transfer vector should have minimal activation of innate immune 
signaling to allow efficient gene delivery without immune activation. On the other hand, 
adenoviral vector-based vaccine antigen delivery could benefit from adenovirus’s intrinsic 
property of innate immune activation that results in efficient activation of transgene-specific 
adaptive immune responses. Therefore, careful engineering of adenoviral vectors can serve 
the purpose of both gene and vaccine antigen delivery.
2.3.2. Adaptive immunity
The adaptive immune responses to adenoviruses are directed against both early and 
late viral proteins. They include both neutralizing antibodies and T cells against viral 
surface antigens such as hexon, penton, and fiber proteins. However, these adaptive 
immune responses against adenoviral antigens also present major obstacles in adenovi-
ral vector development as gene delivery, and vaccine antigen carriers limit the number of 
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administrations that can be done and reduce the efficiency of transgene expression. Both 
humoral and cellular immune responses are discussed in detail in the following sections.
2.3.2.1. Humoral immunity
The surface antigens of adenovirus, penton, hexon, and fiber proteins are involved in host 
cell receptor interaction and can be neutralized by antibodies. The impact of neutralizing 
antibodies (nAbs) on adenoviral gene and antigen delivery has been studied extensively 
[80–82]. The passive transfer of serum from Ad immune mice or purified nAbs against 
adenoviruses decreases the vector transgene expression and induction of transgene-specific 
cellular and humoral responses. Depletion of antibodies against fiber, penton, and hexon 
by affinity chromatography has been shown to significantly enhance the transgene expres-
sion and induced immune responses. Furthermore, hexon-specific antibodies seem to play 
a relatively dominant role in vivo in comparison to other antigens. The hexon-specific nAbs 
are directed against exposed hypervariable loop-containing regions (HVR) on the surface 
of the virus particle. The pre-existing immunity to a prevalent human adenovirus 5 (HAd5) 
can be overcome by replacing the entire HAd5 hexon sequence of exposed epitopes with the 
HVR from a different serotype [6, 82–84]. Consequently, three amino acid substitutions in 
one of the HVRs significantly reduced neutralization by polyclonal serum raised against a 
chimpanzee Ad serotype 68 (ChAd68)-derived vector [83, 85]. Conversely, replacing SAd24 
hexon with SAd23 into an SAd24/Pan7 vector resulted in reduced transgene expression in 
mice with pre-existing SAd23/Pan6 immunity [86]. Additionally, nAb against Ad fiber has 
a minimal effect in vivo as shown in a mouse study where nAbs induced by HAd7 admin-
istration weakly neutralized HAd7 fiber-expressing chimeric HAd5 vector, indicating 
that other non-fiber capsid protein-specific nAbs also have a major role in neutralization. 
Although these in vivo animal studies shed light on the relative importance of pre-existing 
fiber-specific nAbs, they do not accurately reflect the impact of preexisting immunity on 
adenovector efficiency in humans. In most of these animal studies, the pre-existing fiber-
specific nAbs were induced by a single administration of Ad, which induced nAbs with 
poor breadth and at far lower levels than in humans exposed to repeated natural Ad infec-
tions. The nAbs against other surface antigens such as penton may also work against Ad 
in a synergistic fashion along with fiber-specific nAbs. Together, these factors contribute 
to more effective neutralization of Ad-based vectors and result in poor transgene expres-
sion and induced transgene antigen-specific immunity in humans. Importantly, Ad-specific 
nAbs are mostly serotype-specific and have very limited to no neutralization capability of 
other serotypes. This serotype-specificity is due to high sequence heterogeneity of epitopes 
in the hexon HVR and fiber knob among different Ad serotypes. Moreover, the nAbs are 
not the only factor in pre-existing Ad immunity; non-neutralizing Abs can also hamper 
Ad vector efficacy via Fc receptor-dependent cytotoxicity, complement-mediated lysis, and 
opsonization. In humans, Ad infections are very common and nearly everyone contains 
some levels of Ad-specific antibodies. The high seroprevalence of Ad-specific antibodies 
is a major roadblock in adenoviral vector development, and strategies to circumvent these 
must be examined.
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2.3.2.2. Cellular immunity
In humans, Ad vector-specific CD4+ Th1 cells have been detected, but the frequencies of these 
cells decrease with age [87]. The CD8+ T cell responses to different structural proteins have 
also been detected in animals in response to adenovirus infection or adenovector administra-
tion [19, 80, 88]. Due to extensive homology between different adenoviral structural antigens, 
both human and mouse-derived CD4+ and CD8+ T cells cross react with human and simian Ad 
serotypes [20, 89, 90]. Similar to nAb, pre-existing Ad-specific T cells can also reduce Ad vector 
transgene expression and immunity. Furthermore, Ad-specific T cells have been detected in 
80–100% of human subjects in various studies, which make them even more important in Ad 
vector development [89]. The human studies examining both nAbs and T cells demonstrated 
a higher proportion of individuals possessing T cell responses compared to nAbs against Ad. 
The pre-existing Ad-specific T cells have greater consequences for Ad vaccine vector develop-
ment due to their cross-reactive nature, higher distribution in the human population, and 
their multifunctional nature [22]. Finally, human Ad vector has also recently been reported to 
induce cross-reactive hepatitis C virus-specific humoral and cellular immune responses [91]. 
Widespread use of adenoviral vectors in humans will induce such cross-reactive immune 
responses at high levels, which might be beneficial or detrimental in the development of natu-
ral immunity against HCV and affect the immunopathology and disease progression of HCV 
infection.
3. Adenoviral vectors
3.1. Construction of adenoviral vectors
Adenoviruses are engineered to make them safe and efficient for human use as vaccine and 
gene and cancer therapy vectors by deleting certain genome sequences. Initially, human 
adenoviruses, especially adenovirus 5 (HAd5), were developed as gene delivery vectors. 
Since the first generation of adenoviral vectors, based on E1 deletion, a number of different 
strategies have been employed to further improve the gene-carrying capacity and safety by 
deleting more genes. These strategies can be summarized under following three categories.
3.1.1. First generation
First-generation adenoviral vectors were prepared by deleting early gene E1 to render 
them replication-defective and create space for a transgene sequence of up to 4.5 kb [92]. 
Since these vectors lack the E1 region essential for their replication, cell lines such as 
human embryonic kidney cells (HEK293) were engineered to incorporate viral E1 region 
[93]. The E1 region in the HEK293 cell line provides trans-complementation and allows the 
replication of the adenoviral vector [94–97]. These adenoviral vectors carry native tissue 
transduction capability and efficiently express the transgene in target host cells. However, 
there are possibilities of spontaneous homologous recombination between vector and E1 
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regions during amplification inside HEK293 cells, which might enable replication compe-
tent adenoviral (RCA) vectors to emerge [98]. To mitigate this problem, another cell line, 
human embryonic retinoblasts (PERC.6), was made by inserting an expression cassette for 
the adenoviral E1 region with its own promoter (ubiquitous phosphoglycokinase, PGK) 
[99]. This eliminates the adenoviral vector homologous regions from the E1 promoter and 
therefore the chances of recombination [100]. Adenoviral E3 region proteins are known to 
inhibit immunological pathways [101]. Therefore, the adenoviral E3 region was removed 
either partially or completely without affecting in vivo viral amplification [102]. These 
deletions in E1 and E3 regions allowed insertion of even larger cargo sequences (up to 
8 kb) of two independent genes [103]. Due to the absence of the E1 region, adenoviral 
vectors are not able to transcribe other early and late viral proteins, although host cellular 
factors enable these proteins to be expressed at very low levels. This low-level expression 
of viral protein and subsequent presentation on the cell surface by MHC class I molecules 
induce robust cytotoxic T cell immune responses. Deletion of E1 is additionally beneficial 
since adenoviral proteins have toxic effects and induce cell death in a dose-dependent 
manner [104, 105] (Figure 2A–C).
3.1.2. Second generation
Second-generation adenoviral vectors possess deletions in E2 or E4 regions that encode 
for proteins required for replication in target cells [106–108]. These deleted proteins were 
complemented in trans by cell lines (such as HEK293) to allow for vector propagation. These 
second-generation vectors provided additional space for larger cargo sequences (10.5 kb) 
with up to four independent expression cassettes and eliminated the possibility of generating 
replication-competent adenoviruses during amplification. This deletion of early viral genes 
impacts the amplification of viral vector in cell culture and results in lower yields due to 
inefficient complementation by the producer cell lines [107, 109]. These vectors also have been 
reported to have lower transgene expression. Immunogenicity and cellular toxicity are still a 
major concern in the second-generation adenoviral vectors [110] (Figure 2A–C).
3.1.3. Third generation
Third-generation adenoviral vectors are also called “high capacity adenoviral vectors” 
(HCAds) because they can accept cargo sequences up to 36 Kb [111–113]. The HCAds 
were generated by deleting all viral sequences except the ITRs and the packaging signal 
[114]. For replication of third-generation adenovirus vectors in cell culture, instead of the 
complementation by the viral genes encoded by host cells, an additional adenoviral helper 
virus is provided. Therefore, the third-generation adenoviral vectors are also called helper-
dependent or “gutless” adenoviral vectors [115–117]. The helper adenovirus is generated 
like a first-generation adenoviral vector and includes packaging signal flanking loxP sites. 
The vector is produced in HEK293 cells that constitutively express Cre recombinase by 
simultaneously transducing helper virus and the HCAd genome. This allows the syn-
thesis of adenoviral proteins by the helper virus and enables assembly of viral capsids, 
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resulting in the packaging of HCAd genome only. The helper virus genome-packaging sig-
nal is excised by Cre-mediated recombination of the loxP sites, thus preventing helper virus 
genomes from assembling into viral particles. In some production systems, other recombi-
nases like Saccharomyces cerevisiae-derived Flp recombinase [118] or bacteriophage-derived 
phiC31 integrase [119] have also been used. Third-generation vectors have several benefits 
over first- and second-generation adenoviral vectors. These include less cellular toxicity 
and reduced immunogenicity [120, 121], thereby providing a flexible vector system that 
Figure 2. Methods of preparation of different types of adenoviral vectors. (A) First generation. The target gene is cloned 
into a shuttle vector containing 5′-ITR, a packaging signal, and the sequence for homologous recombination. This shuttle 
vector and an adenoviral backbone vector are transfected into HEK-293 cells, and adenoviral vector is created through 
homologous recombination between the two vectors. (B) First or second generation. The target gene is cloned into a 
shuttle vector that contains 5′-ITR, a packaging signal, and an LoxP site(s). This shuttle vector and a LoxP-containing 
adenoviral backbone vector are joined together through Cre recombinase-mediated recombination either in vitro or 
in HEK-293 cells. (C) First or second generation. The target gene is cloned into a shuttle vector containing 5′-ITR, a 
packaging signal, and a kanamycin-containing bacterial replication sequence flanked with two homologous arms. The 
homologous recombination between the linearized shuttle vector and ampicillin-resistant adenoviral backbone vector 
takes place in bacterial cells (BJ5183), and adenoviral plasmids are selected on kanamycin. This plasmid is linearized 
and transfected in HEK-293 cells for adenoviral vector production. (D) Third generation. The target gene is cloned into 
a transfer vector that only contains ITRs and a packaging signal. A helper adenovirus is used to generate the adenoviral 
vector. Modified HEK-293 cells are used for adenoviral production, which prevent packaging of helper adenovirus due 
to deletion of packaging signal. Figure is adapted from Ref. [209].
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efficiently transduces host cells due to reduced induction of anti-adenoviral neutralizing 
antibodies [118, 122]. The HCAds can simultaneously encode multiple transgene cassettes. 
Although the HCAds provide a much superior vector system, they are more complicated to 
generate compared to previous generations of adenoviral vectors and also have possibility 
of helper virus contamination due to inefficient Cre-mediated excision of the helper virus 
packaging signal [123] (Figure 2D).
3.2. Current applications of adenoviral vectors
Since their first use in gene therapy, adenoviral vectors have progressed significantly and 
are currently being tested clinically in several gene therapy, vaccine vector, and anticancer 
studies.
3.2.1. Gene therapy
Adenoviruses have a unique ability to infect a broad range of cell types. Therefore, ade-
novirus-based vectors can be used to transduce and deliver transgenes to different cell 
types including both replicating and quiescent cell populations. This property of adenovi-
ral vectors is extremely important in gene therapy and puts adenoviral vectors on top of 
viral vectors for gene delivery. Furthermore, adenovirus vectors do not integrate into host 
genomes but stay as episomal DNA in the nucleus of host cells. Modern adenoviral vectors 
can take multiple gene cassettes, up to 36 kb of foreign DNA, which make them suitable for 
delivering virtually any size of gene. In 1992, for the first time, a first-generation adenovi-
ral vector was used to deliver and express alpha-1 antitrypsin (A1AT) in hepatocytes of a 
patient who had alpha-1 antitrypsin deficiency [124]. In another study, an E1–E3 deleted 
HAd5 adenoviral vector was used to deliver an A1AT gene to lung tissues [125]. Later, 
using adenoviral vectors, a number of attempts were made to deliver dysfunctional or 
deficient genes, which were responsible for several human genetic diseases and condi-
tions. Cystic fibrosis is one such human genetic disease, in which the gene CFTR (cystic 
fibrosis transmembrane conductance regulator) becomes dysfunctional due to mutation. 
Adenoviral vector was used to deliver CFTR genes to lung tissues [126]. In another study, 
the adenoviral vector was used to deliver the gene for ornithine transcarbamylase, which 
is required in the urea cycle and is responsible for ornithine-transcarbamylase deficiency 
[127, 128]. These studies faced several challenges including humoral and cellular immu-
nity to adenoviral vectors upon repeated administration of vector, cellular cytotoxicity, 
and oncogenesis [129]. These trials raised serious safety concerns for using adenoviral 
vectors in gene therapy and resulted in a sharp decline in their use. The reasons for these 
problems were studied extensively and addressed by constructing new adenoviral vec-
tors. The adenoviral immunogenicity and cytotoxicity were suspected to be due to low-
level expression of several viral proteins. The newer generations of adenoviral vectors had 
these adenoviral genes removed, and hence the vector immunogenicity and toxicity were 
significantly reduced. The new generations of adenoviral vectors have raised new hope in 
adenoviral vector-based gene delivery. Currently, a number of gene therapy clinical trials 
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are ongoing with adenoviral vectors (Table 1). The previous generation of adenoviral vec-
tors is still in use for vaccine antigen delivery due to their inherent capability of inducing 
robust humoral and cellular immune responses.
3.2.2. Vaccine vector
As described earlier, adenoviruses activate several innate immune signaling pathways that 
result in the secretion of a number of proinflammatory cytokines. These proinflammatory 
cytokines pave the way for effective immune cell stimulation and result in the induction of 
robust adaptive humoral and cellular immune responses. To resolve infections with intracel-
lular pathogens such as viruses, CD8+ cytotoxic T lymphocyte (CTL) responses are critical. 
Transgene antigens carried by adenoviral vectors are presented to T cells via MHC class I 
molecules, and therefore, they induce efficient and robust CTL responses. The CTLs effi-
ciently recognize and kill virus-infected cells, intracellular pathogens, and cancerous cells. 
These properties make adenoviral vectors promising as vaccine vectors. A number of human 
clinical trials have been conducted for adenoviral vector-based vaccines against different 
infectious diseases including Ebola virus, Zika virus, influenza viruses, HIV, Mycobacterium 
tuberculosis, and malaria [21, 130].
An HAd5 vector-based HIV vaccine containing clade B sequences of gag/pol and nef genes 
was tested in several clinical trials by Merck during 2003–2006 [131]. These studies dem-
onstrated that a majority (80%) of vaccine recipients induced T cells with a magnitude of 
275–300 IFN-γ producing cells per million peripheral blood mononuclear cells (PBMCs), 
where about 50% vaccinees had detectable and durable HIV-specific CD8+ T and CD4+ T 
cells. This is far greater than any other T cell vaccine at that time [132–135]. These results 
were very encouraging and led to a multinational STEP trial involving about 3000 sub-
jects in 2005 [136, 137]. The early results of this vaccine indicated that vaccine was well 
S. 
no.
Adenoviral vector 
(biologic)
Modification Transgene Target/
condition
Phase ClinicalTrials 
identifier
1 HAd5-CB-CFTR E1 deleted Cystic fibrosis 
transmembrane conductance 
regulator (CFTR) gene
Cystic fibrosis I NCT00004779
2 HAd5-hAQP1 E1 deleted Human aquaporin-1 
(hAQP1)
Parotid salivary 
dysfunction
I NCT00372320
3 HAd5-PDGF-B E1 deleted Platelet-derived growth 
factor B (PDGF-B)
Varicose ulcer I NCT00000431
4 HAd5-PEDF 
(AdGVPEDF.11D)
E1, E3 and E4 
deleted
Pigment epithelium-derived 
factor (PEDF) protein
Macular 
degeneration
I NCT00109499
5 HAd5-VEGF E1–E3-deleted Vascular endothelial growth 
factor D (VEGF-D) gene
Angina pectoris/
myocardial 
infarction
I NCT01002430
Table 1. Gene therapy: adenoviral vectors in clinical trial.
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tolerated upon repeated vaccination and induced robust T-cell responses to HIV antigens. 
Despite these early findings, the STEP trial had to be terminated prematurely in 2007 due to 
enhanced acquisition of HIV infection in the vaccine group compared to placebo [137, 138]. 
A total of 82 cases of HIV infection were recorded in the trial participants, 49 cases were in 
vaccine recipients and 33 were in placebo group. Another interesting observation was that 
the HIV infection rate was twofold higher in men with prior adenovirus type 5 infection 
(Ad5 titers >18) versus placebo recipients [135, 139]. The same HAd5 clade B gag/pol and 
nef genes-based vaccine was tested in another companion Phambili clinical trial in a South 
African population. The goal was to investigate whether this vaccine would be efficacious 
against clade C HIV infections. The participants had different prevalent modes of sexual 
transmission, different subtypes of HIV-1, and varying Ad5 seroprevalence. Unfortunately, 
this trial also had to be stopped due to acquisition of HIV infection in 9 females seropositive 
for HAd5 out of a total of 11 cases. Of these 9 cases, 6 were vaccinees [140, 141]. These results 
indicated that pre-existing immunity to the Ad5 vector is an important risk factor for HIV 
acquisition among vaccine recipients. Such profound effects of pre-existing Ad5 immunity 
on HIV acquisition were not observed in previous studies in non-human primates (NHP) 
using an adenovirus vector-based vaccine [142]. Several hypotheses were provided for the 
failure of the STEP trial but none of the hypotheses were proven after experimentation, and 
the mechanisms for higher HIV acquisition in vaccinees with pre-existing Ad immunity still 
remain unclear. These results shocked the vaccine community and raised serious questions 
regarding the fate of adenoviral vectors in vaccine approaches.
In 2009, another famous HIV vaccine clinical trial (HVTN phase II) was started [143]. It 
utilized a heterologous prime-boost strategy, in which vaccinees were first primed with 
a DNA-based vaccine expressing HIV proteins (envA, envB, envC, gagB, polB, nefB) fol-
lowed by a booster Ad5 vector vaccine having matching HIV antigens as transgenes. This 
trial too met with the same fate as STEP, as the vaccine failed to reduce the HIV acquisition 
rate or attenuate the disease in infected subjects. It was terminated in 2013 prior to comple-
tion. However, this study and several other studies provided evidence of superior response 
rates, induction of broader T cell immune responses with well-accepted tolerance, by heter-
ologous prime-boost vectors compared to homologous vaccination [144]. This started a new 
vaccination regimen involving priming with one type of adenoviral vector and boosting 
with another adenoviral vector derived from novel serotypes such as HAd26 and HAd35. 
This allowed for repeated vaccination and also vaccination in individuals with pre-existing 
vector immunity [145–149]. Currently, a number of non-human adenoviral vectors such as 
chimpanzee and bovine are also being utilized to avoid pre-existing vector-specific immu-
nity [18, 21, 150–152].
Due to the emergence of life-threatening infectious diseases such as Ebola and Zika viruses, 
an immediate need for vaccines for these pathogens was recognized. These urgent needs 
attracted researchers toward viral vector platform-based vaccines, especially extensively 
studied and improved vector technology, and adenoviral vectors became the focus of several 
vaccines against these infectious diseases [21, 130]. Adenoviral vector-based vaccines are easy 
to design and to produce on a mass scale, which is of paramount significance for clinical 
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use. Therefore, three adenoviral vector-based vaccines encoding Ebola virus glycoprotein, 
ChAd3-ZEBOV1 from GlaxoSmithKline [153], Ad26-ZEBOV/MVA-BN-Filo2 from Johnson & 
Johnson [154], and HAd5 from the Chinese federal agency [155] were quickly generated and 
tested in macaques. Each of them proved to be well tolerated, immunogenic, and protective in 
macaques. All these vaccines were also well tolerated, safe, and immunogenic in phase I clini-
cal trials, and the ChAd3- and ChAd26/MVA-based vaccines progressed further into phase 
II and phase III efficacy trials [156, 157]. The Chinese Ad5-based Ebola vaccine showed less 
efficacy in phase I clinical trial in individuals with pre-existing adenoviral immunity [158]. 
Beside these, a chimpanzee adenoviral vector ChAd63 prime/MVA boost-based malaria vac-
cine, which contains Plasmodium falciparum-derived ME-TRAP antigen, showed a significant 
enhancement in antigen-specific T cell responses and partial protection against malarial para-
sites in a phase I clinical trial [156, 159].
Despite initial setbacks, adenoviral vector-based vaccines are still very attractive and promis-
ing vaccine platforms. Currently, several adenoviral vector-based vaccines are in different 
stages of clinical development (Table 2).
3.2.3. Cancer immunotherapy
Several DNA viruses such as reo, measles, herpes simplex, Newcastle disease, and vaccinia 
have been tested in clinical trials for anticancer immunotherapy. The mechanism of antican-
cer activity of these viruses is multipronged. One mechanism involves selective infection 
and replication in tumor cells where expression of viral antigens or oncogenes inside the 
cancer cell changes the tumor microenvironment by inducing proinflammatory cytokines. 
These subsequently attract immune cells to the tumors eventually resulting in lysis of the 
tumor cells. Another mechanism uses vectors to deliver gene(s) whose expression results 
in the apoptosis of cancer cells or lysis of cancer cells due to replication by replication-
competent viral vectors [160, 161]. Adenoviral vector technologies have progressed to the 
clinical stage for various cancers and also have been approved in some countries for use in 
human [162–164].
Various anticancer approaches have been tested using adenoviral vectors. One of these 
approaches depends on the induction of immune responses by delivering specific tumor-
associated antigen as a vaccine, which activates immune cells against the tumor [165–168]. 
Due to immunogenic properties of adenoviral proteins such as capsid, adenoviral vectors 
induce robust CTL responses, which eventually kill the tumor cells expressing these tumor 
antigens. However, this vaccination strategy has shown limited success in cancer.
Another approach uses conditional replicative adenoviral vector (CRAd) to preferentially 
replicate inside a tumor cell and eventually lyse it through a lytic replication [162]. This strat-
egy takes advantage of the conducive nature of cancer cells toward adenoviruses. Adenoviral 
vectors have been modified to efficiently carry out oncolytic replication in cancer cells while 
limiting their replication in healthy cells [9, 169]. An adenoviral vector with a partial E1B gene 
deficiency called ONYX-015 became the first ever adenoviral vector to enter clinical trial in 
1996 [169]. The ONYX-015 is unable to replicate in healthy cells expressing p53 but replicates 
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S. 
no.
Adenoviral vector 
(biologic)
Modification Transgene Target/
condition
Phase ClinicalTrials 
identifier
1 HAd5-EBOV E1-deleted Glycoprotein Ebola virus 
disease
II NCT02575456
2 ChAd3-EBO-Z E1-deleted Glycoprotein Ebola virus 
disease
I/II NCT02289027
3 ChAd3-EBO-Z/
MVA-EBOV-Z-BN-Filo 
Prime/Boost
E1-deleted Glycoprotein/envelope 
filovirus
Ebola virus 
disease
I NCT02267109
4 Ad26-EBOV-Z/MVA-
BN-Filo Prime/boost
E1 and E3 
deleted
Glycoprotein Ebola virus 
disease
I NCT02891980
5 Ad26-EBOV-Z/MVA-
BN-Filo Prime/boost
E1 and E3 
deleted
Glycoprotein Ebola virus 
disease
III NCT02661464
6 HAd6-Nsmut/
VhAd3NSmut or 
CHAd3NSmut/
HAd6NSmut Prime/
boost
E1-deleted Non-structural protein Hepatitis C I NCT01070407
7 AdCh3NSmut/
Ad6NSmut
E1-deleted Non-structural protein Hepatitis C I NCT01094873
8 HAd5-HA (VXA-1.1) E1-deleted Hemagglutinin and 
double-stranded RNA 
as an adjuvant
Influenza 
H1N1
II NCT02918006
9 HAd5-HA E1/E3-deleted Hemagglutinin Influenza 
H5N1
I NCT00755703
10 HAd4-HA5-Vtn HA E3-partial 
deletion
Hemagglutinin Influenza 
H5N1
I NCT01006798
11 HAd35-CSP/HAd26-
CSP Vectors Prime/
boost
E1 and E3 
deleted
Circumsporozoite 
(CSP) antigen
Malaria I/II NCT01397227
12 HAd5 
(NMRC-M3V-Ad-PfCA)
E1, E4 
deleted, E3 
partially 
deleted
Circumsporozoite 
(CSP) antigen, apical 
membrane antigen 1 
(AMA1)
Malaria I/II NCT00392015
13 ChAd63-ME-TRAP/
MVA-ME-TRAP 
poxvirus Prime/boost
E1-deleted ME-TRAP antigen 
(pre-erythrocytic 
thrombospondin-
related adhesion 
protein)
Malaria I NCT01373879
14 HAd35-TB Antigens/
MVA85A Prime/boost 
(AERAS-402, BCG)
E1-deleted, 
HAd5 E4 orf6 
replaced
TB antigens: Ag85A, 
Ag85B, and TB10.4
Tuberculosis I NCT01683773
15 HAd35-TB Antigens 
(AERAS-402)
E1-deleted, 
HAd5 E4 orf6 
replaced
TB antigens: Ag85A, 
Ag85B, and TB10.4
Tuberculosis II NCT02414828
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in p53-deficient tumor cells and results in the lysis of the cell, taking advantage of the cancer 
cell environment that supports vector replication [9]. The ONYX-015 has been proven to be 
safe and well tolerated in patients with various advanced cancers and is reported to be even 
S. 
no.
Adenoviral vector 
(biologic)
Modification Transgene Target/
condition
Phase ClinicalTrials 
identifier
16 Four HAd5 vectors 
for four HIVAntigens 
(VRC-HIVADV014-
00-VP/VRC-
HIVADV014-00-VP)
E1, E4 and 
partial E3 
deleted
HIV antigens 
gp140(A), gp140(B)
dv12, gp140(C) and 
GagPol(B)
HIV 
infections
I NCT01549509, 
NCT00119873, 
NCT00091416, 
NCT00709605, 
NCT00102089
17 Plasmid DNA 
expressing Gag, Plo 
and Nef +Four HAd5 
vectors for four 
HIVAntigens (VRC-
HIVDNA016-00-VP/
VRC-HIVADV014-
00-VP), DNA + HAd5/
HAd5 Prime/boost
E1, E4 and 
partial E3 
deleted
HIV antigens 
gp140(A), gp140(B)
dv12, gp140(C) and 
GagPol(B)
HIV 
infections
I/II NCT00123968, 
NCT00125970
18 Plasmid DNA vaccine/
HAd5-HIV-1 (VRC-
HIVDNA016-00-VP/
VRC-HIVADV014-
00-VP) prime/boost
E1, E4 and 
partial E3 
deleted
HIV antigens 
gp140(A), gp140(B)
dv12, gp140(C) and 
GagPol(B)
HIV 
infections
II NCT00865566
19 DNA Vaccine/
HAd35/HAd5 (VRC-
HIVDNA044-00-VP/
VRC-HIVADV027-
00-VP/VRC-
HIVADV038-00-VP) 
HAd35/HAd5 prime/
boost or DNA/HAd5 
prime/boost or DNA/
HAd35 prime/boost
E1-deleted Gag, pol and Nef 
antigens
HIV 
infections
I NCT00801697
20 HAd26 (HAd26.
ENVA.01)
E1 and E3 
deleted
Env gp140 HIV 
infections
I NCT00618605, 
NCT01103687
21 HAd4-mgag, HAd4-
EnvC150 alone or 
combination
Replication 
competent
mosaic HIV Gag 
antigen, HIV clade C 
Env protein (gp150 
1086.C)
HIV 
infections
I NCT02771730, 
NCT01989533
22 rcAd26.MOS1.HIV-Env 
1
E3 or E3/E4 
deleted
HIV-1 Mos1Env HIV 
infections
I NCT02366013
23 Ad26.Mos.HIV (Ad26.
Mos.1.Env + Ad26.
Mos1.Gag-Pol + Ad26.
Mos2.Gag-Pol)/MVA-
Mosaic prime/boost
E3 or E3/E4 
deleted
Hiv gag, pol and Env HIV 
infections
I/II NCT02919306
Table 2. Vaccine delivery: adenoviral vectors in clinical trials.
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more effective when administered in combination with standard chemotherapy [169, 170]. A 
similar adenoviral vector named Oncorine or H101, developed by Shanghai Sunway Biotech, 
was approved by the Chinese Food and Drug Administration agency for the treatment of 
head and neck cancer [171, 172]. To further enhance the efficacy, potency, and specificity of 
the oncolytic adenoviral vectors, a new generation of adenoviral vectors is being tested. These 
new adenoviral vector systems carry a suicide gene like HSV thymidine kinase or a cytotoxic 
prodrug under the control of tumor gene/antigen promotor like prostate antigen promotor 
[173–175].
In some studies, replication-deficient or replication-competent adenoviral vectors were 
used to deliver transgenes, which express a tumor suppressor protein or cytotoxic/sui-
cide protein that induces cell cycle arrest or a death cascade [176, 177]. More than 50% of 
cancers have a mutation in tumor suppressor gene p53. Advexin is a replication-deficient 
adenoviral vector that expresses p53 through a CMV promotor. It was tested in both pre-
clinical and more than a dozen phase I/II clinical trials and proved to be well tolerated and 
efficacious against colorectal cancer, hepatocellular carcinoma (HCC), non-small cell lung 
cancer (NSCLC), prostate cancer, breast cancer, ovarian cancer, bladder cancer, glioma, 
and squamous cell carcinoma of the head and neck [171, 178, 179]. Gendicine, a similar 
adenovirus vector developed by a Chinese Biotech Company, Shenzhen SiBiono GeneTech, 
differs only in that its transgene promotor is from Rous Sarcoma Virus. In 2003, Gendicine 
was approved by the Chinese Food and Drug Administration agency as a first-ever gene 
therapy product to be used in combination with chemotherapy to treat head and neck 
squamous cell carcinoma [4, 178, 180]. Since then, Gendicine has been tested in a num-
ber of clinical trials against different types of cancers such as HCC, NSCLC, malignant 
glioma, and epithelial ovarian carcinoma. It is reported to be well tolerated and provide 
progression-free long-term survival benefits in combination regimens when compared to 
standard therapies alone [4, 178, 180, 181]. Therefore, adenoviral vectors have been clini-
cally successful in anticancer therapy and have shown tremendous potential in the treat-
ment of several cancer types [4, 171, 180, 181]. However, there is still scope for further 
improvements in clinical efficacy and safety (Table 3).
3.3. Challenges and solutions to adenoviral vectors use
Development of adenoviral vectors has come a long way since their first use. Currently, dif-
ferent types of adenoviral vectors are available for different applications. In the beginning, 
a high prevalence of pre-existing immunity to adenoviral vectors was considered as a seri-
ous concern for their use in mass vaccination and gene therapeutic applications. Further, 
immunogenicity, cellular toxicity, and oncogenesis were also major obstacles in gene therapy 
applications. Many other concerns, such as the possibility of vectors regaining replication 
competence, non-specificity, immunodominance of adenoviral antigens over the vaccine 
transgene antigen(s), immune modulation by viral antigens, heterologous immunity with 
other pathogens, are still evident in many adenoviral vector-based vaccine and gene therapy 
approaches [182]. These are discussed in the following sections.
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3.3.1. Tissue tropism and transgene expression
Adenoviruses can infect a diverse range of mammalian cell types. Infection to host cells 
is mediated by binding of adenoviral fiber protein to host cell surface receptors followed 
by recruitment of RGD motifs on penton bases to bind the host cell alpha-integrins. Most 
S. 
no.
Adenoviral vector (biologic) Modification Transgene Target/condition Phase ClinicalTrials 
identifier
1 ICOVIR-5 E2F-E1A Δ24 
RGD
— Solid tumors I NCT01864759
2 LOAd703 5/3 Δ24 CD40L & 4-1BBL Pancreatic cancer I/IIa NCT02705196
3 HAd5-yCD/
mutTKSR39rep-hIL12
E1B-55K Cytosine 
deaminase (CD)/
tyrosine kinase 
(TK) hIL12
Prostate cancer I NCT02555397
4 ONCOS-102 with 
cyclophosphamide
5/3 Δ24 GM-CSF Advanced 
neoplasms
I NCT01598129
5 VCN-01 with or without 
abraxane and gemcitabine
DM-1-E2F-
E1A Δ24 
RGD
Hyaluronidase Advanced solid 
tumors
I NCT02045602
6 VCN-01 with abraxane and 
gemcitabine
DM-1-E2F-
E1A Δ24 
RGD
Hyaluronidase Advanced 
pancreatic cancer
I NCT02045589
7 CG0070 E2F-E1A Granulocyte 
macrophage 
colony-
stimulating factor 
(GM-CSF)
Bladder cancer III NCT02365818
8 CG0070 E2F-E1A GM-CSF Bladder cancer II/III NCT01438112
9 Colo-Ad1 Ad11p/Ad3 — Colon, non-small 
cell lung cancer, 
bladder, renal 
cancer
I NCT02053220
10 DNX-2401 with 
Temozolomide
E1A Δ24 
RGD
— Glioblastoma 
multiforme
I NCT01956734
11 DNX-2401 with IFNγ E1A Δ24 
RGD
— Brain tumors I NCT02197169
12 Ad5-yCD/mutTKSR39rep-
ADP with intensity-
modulated radiation therapy 
(IMRT)
E1B-55K CD/TK Prostate 
carcinoma
II/III NCT00583492
13 OBP-301 hTERT — Hepatocellular 
carcinoma
I/II NCT02293850
Table 3. Oncolytic therapy: adenoviruses in clinical trial.
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common human adenoviruses (HAd5 and HAd2) bind to coxsackie adenovirus receptor 
(CAR) present on many different cell types including epithelial, endothelial, hepatocytes, 
myoblasts, and heart muscle cells. Some cells such as lymphocytes do not express CAR 
themselves but harbor CAR-recognizing adenoviruses. Adenovirus from subgroup B such 
as HAd35 do not bind to CAR but recognize another complement regulatory receptor 
CD46 present on most nucleated human cells, hematopoietic stem cells, and dendritic cells. 
Another subgroup B adenovirus HAd3 binds to CD80 and CD86 costimulatory molecules 
on antigen-presenting cells [8, 166, 183, 184]. Other cellular receptors such as integrin αvβ5, 
heparin sulfate proteoglycans, and sialic acid have also been reported to aid adenoviral 
entry to the cells [30–32, 185].
3.3.2. Pre-existing adenoviral immunity
The impact of pre-existing immunity against adenoviral vectors has been discussed in the 
previous section under adaptive immunity. To avoid the pre-existing immunity against 
adenoviral vectors, several strategies are being employed as discussed below.
3.3.2.1. Use of alternative less frequent adenoviruses for vector
Several human adenoviruses with low seroprevalence such as HAd2, HAd26, and HAd35 
were identified and developed into vectors [186]. The seroprevalence of these rare human 
adenovirus serotypes is very low, and hence the effect of pre-existing immunity is minimal 
[81, 187]. HAd26 and HAd35 vectors have been tested in phase I clinical trials and proven to 
be safe. However, the immunogenicity and efficacy of these low seroprevalence vectors are 
reported to be lower in comparison to more prevalent HAd5. These results are very concern-
ing and warrant further investigation to find the reasons for the poor performance of these 
vectors. The nAb and T cells against HAd5 do not cross react with HAd35 but nAbs and T 
cells against another common serotype, HAd2, cross react with HAd35 and reduce the immu-
nogenicity and efficacy of the HAd35 vectors [188, 189].
To avoid the cross-reactive immunity due to closely related serotypes of Ad, more genetically 
distant Ad serotypes including animal and bird Ad were developed as viral vectors. Among non-
human adenovirus vectors, chimpanzee-derived adenovirus vector (ChAd) is the most widely 
used. In comparison to HAd, the nAbs against ChAd have been found to be less prevalent. For 
example, nAbs against ChAd7 were detected in only 15% of American, European, Chinese, 
and African population [186]. Similarly, nAbs against ChAd6 are also low in these populations 
except Africans, which have about 40% ChAd6-specific nAbs [81, 186]. Several chimpanzee ade-
noviral vector-based vaccines, such as ChAd7 for Ebola virus, ChAd6 for rabies, and ChAd6, 
ChAd7, and ChAd9 for malaria, have shown high efficacy in animal models [190]. Furthermore, 
ChAd63-based malaria and ChAd3-based hepatitis C virus vaccines have shown to be safe and 
highly immunogenic in phase I clinical trial [191, 192]. Despite low seroprevalence of ChAd 
vectors in humans, pre-existing cross-reactive T cells against many conserved viral antigens are 
still a major concern. The HAd-induced ChAd cross-reactive T cells have been reported against 
ChAd6, ChAd7, ChAd24, ChAd32, and ChAd68 [22, 80, 89, 90]. The negative effects of these 
cross-reactive T cells on ChAd have been demonstrated in several animal models [22, 89]. The 
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impact of the pre-existing cross-reactive T cells could be far greater in the clinical setting where 
humans are repeatedly exposed to various serotypes of adenovirus and carry a far broader 
diversity and a higher frequency of cross-reactive T cells.
Apart from rare human and chimpanzee adenoviruses, several other adenoviruses derived 
from animals such as bovine, porcine, ovine, canine, and fowl are also being explored for 
vector development [151, 193–195]. The human population lack nAbs against these adeno-
viruses, and therefore, the vectors derived from these adenoviruses could be more effica-
cious in comparison to HAd and ChAd. The mouse models with experimentally induced 
pre-existing immunity by the administration of HAd vector demonstrated a lack of nAbs 
and CD4+ T cells against PAd3 and BAd3 [18]. Furthermore, BAd3- or PAd3-based influ-
enza virus vaccine demonstrated high efficacy even in the presence of pre-existing HAd5 
immunity. There was also no effect of pre-existing HAd5 immunity on transgene expression, 
immunogenicity, and efficacy in animal models. However, their potential benefits still need 
to be proven in humans.
3.3.2.2. Routes of immunization
Several studies have reported that different routes of immunizations can negate the detri-
mental effect of pre-existing immunity. This outcome could be at least partly due to evasion 
of tissue-resident Ad-specific T cells when using different routes of immunization. Tissue-
resident CD8 memory T cells remain confined to a specific tissue. As such, they are not sys-
temic and do not prevent Ad vector infection in distant tissues. These tissue-resident T cells 
are induced by tissue-derived migratory dendritic cells during priming, which activate T cells 
with specific tissue-homing molecules [196–198]. In a non-human primate model, HAd5-
induced protective immune responses by intranasal/intratracheal immunization were not 
affected by pre-existing HAd5 immunity that had been induced by intramuscular administra-
tion of an unrelated HAd5 vector [199]. Although this strategy has shown promising results 
in animal models, it has not been verified in humans. This strategy is however restricted by 
limited routes feasible for administration in humans. Moreover, the nAbs induced by adeno-
viral infection or adenoviral vector-based vaccination can be detected in any part of the body, 
which may affect the transgene expression and immune responses irrespective of the alter-
native route used for subsequent adenovector administration. However, nAbs are generally 
present in blood and are in most cases not cross-reactive to different serotypes or subtypes 
and Ads from different host species [200].
3.3.2.3. Heterologous prime-boost strategy
Another strategy to avoid pre-existing adenovector immunity involves the use of heterolo-
gous prime-boost regimens. In this strategy, the priming and boosting are done by using 
different antigen delivery vehicle and/or vectors derived from either different serotypes of 
the same species or vectors from completely different host species, for example, priming 
with DNA and boosting with HAd5 or priming with ChAd68 and boosting with ChAd1 
[201]. Studies have shown that the heterologous prime-boost induces more robust immune 
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responses compared to single vaccination or homologous prime-boost immunizations. 
The cellular immune responses induced by DNA prime and HAd boost were not affected 
by pre-existing HAd5 immunity. These findings were further confirmed in a clinical trial. 
Another preclinical study involving Plasmodium or SARS antigens encoded by Modified 
Vaccinia Ankara (MVA)/adenoviral vector as prime/boost showed induction of robust T cell 
and Ab responses of higher magnitude compared to Ad/DNA regimens. Finally, a ChAd63/
MVA prime-boost strategy is now being evaluated in clinical trials as a vaccine against 
malaria, HIV, and HCV [191, 202–204]. The heterologous prime/boost strategy seems very 
effective in circumventing the pre-existing immunity against adenoviral vectors in stud-
ies conducted so far; however, the vehicle for priming and/or boosting must be carefully 
designed and selected.
3.3.3. Immunodominance over transgene immunity
Adenoviral antigens induce robust antibody and T cell immune responses. Recent stud-
ies have shown that adenoviral-derived epitopes can dominate over the transgene-derived 
epitopes and hinder the induction of transgene-specific immunity. This impairment of 
transgene-specific immune responses in naive vaccinees is due to immune competition. 
Epitopes derived from an adenovirus vector were shown to inhibit the induction of HIV 
GagL85-93-specific CD8+ T cells [205]. This study demonstrated that competition occurs at 
the level of responding CD8+ T cells, and co-immunization with an interleukin 2-encoding 
plasmid restored GagL85-93-specific CD8+ T cell responses in the presence of an adenoviral 
hexon486-494 epitope. The IL2, however, could not restore GagL85-93 responsiveness in 
Ad-based immunization, likely due to the presence of other epitopes in the Ad vector [206]. 
Another study demonstrated that plasmid DNA, but not adenovirus vector-encoding hepa-
titis B surface antigen (HBsAg), primed CD8 T cells against subdominant HBsAg epitopes 
[207]. These studies suggest that adenoviral antigen-specific T-cell immunity is primed 
efficiently during adenoviral vector-based immunization, which can limit the immunoge-
nicity of adenoviral vector-encoded transgenic antigens. These studies highlight the need 
for modifications of the vector or the transgene used in immunization to circumvent or 
dominate over the adenoviral vector-specific epitopes and induce more effective transgene-
specific immunity.
3.3.4. Heterologous immunity induced by adenoviral antigens
We discovered an unusual and interesting phenomenon that non-recombinant HAd5 vec-
tor induces robust cross-reactive immune responses toward hepatitis C virus (HCV) anti-
gens [91]. Upon further investigation, we found that adenoviral proteins contain extensive 
homologies with various peptide epitopes derived from HCV antigens. These observations 
led us to investigate the adenoviral vector-induced HCV cross-reactive immune responses 
in detail in both mice and humans. In mice, we demonstrated that Ad vector alone can 
induce potent, broad anti-HCV cross-reactive immunity that can significantly reduce viral 
load upon challenge with infectious chimeric Vaccinia-HCV. Furthermore, we also detected 
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HCV cross-reactive antibodies and HCV antigen-dependent expression of IFN-γ in T cells 
from a cohort of HCV-naïve but Ad-immune human individuals. Previous studies have 
also reported that one pathogen can induce cross-reactive immunity against an unrelated 
pathogen [91, 208]. This kind of immunity is known as heterologous immunity. Heterologous 
immunity is a double-edged sword, which can modulate the breadth of the T cell repertoire, 
influence the memory T cell pool and/or the immune dominance of a specific epitope, and 
lead to enhanced or diminished immune responses against a pathogen. These observations 
have significant clinical implications on natural history, immunopathogenesis, and disease 
outcome in HCV infection. The widespread use of adenoviral vectors in mass vaccination 
programs might change the immune hierarchy and natural T cell responses against HCV 
antigens and deviate and/or alter the incidence of HCV infection and immune pathogenesis 
in an at-risk population. However, a careful evaluation of adenoviral-induced cross-reactive 
immune responses and their impact on HCV immunity and immunopathology is needed to 
more accurately ascertain the impact of this phenomenon.
4. Conclusions and future prospects
Since their first use as gene delivery vehicles, adenoviral vectors have been extensively stud-
ied in a number of applications and have improved substantially over time. Issues such as 
toxicity, pre-existing immunity in humans, and challenges in construction are continually 
being addressed. More recently, outbreaks of newly emerging infectious diseases, such as 
SARS, Ebola, and Zika, and the continuing threat of bioterrorism have increased the require-
ment of novel vaccine platforms which can be designed and produced in large scale within 
a short period of time. Adenoviral vectors, due to their versatility, ease of construction, 
adeptness to rapid mass production, and induction of robust transgene-specific humoral 
and cellular immune responses, have proven to be valuable in the development of vaccines 
for emerging viral infectious diseases. Furthermore, extensive knowledge about the adeno-
viral vector biology and the induced immune responses in animals have tremendously 
helped in developing effective vaccine candidates against several viral pathogens, which 
have progressed to advanced clinical stages. The adenoviruses are now at the forefront of 
vaccinology and have shown huge potential in both pre-clinical and clinical studies for HIV, 
malaria, Ebola virus, and Zika virus vaccines. Apart from infectious disease, adenoviral vec-
tors have been approved for human use as cancer and gene therapy. Therefore, adenoviral 
vectors have opened new avenues in gene delivery, vaccine antigen delivery, and cancer 
molecular therapy.
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